The Europe HIV Injection Market would witness market growth of 17.4% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe HIV Injection Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $178.5 Million by 2029. The UK market is exhibiting a CAGR of 16.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 18.2% during (2023 - 2030).
Antiretroviral therapy (ART), the known treatment for HIV, entails the daily administration of a combination of HIV medications. ART can lower the risk of HIV transmission and help individuals with the virus live longer, healthier lives, although it cannot cure HIV. The development of effective treatments for HIV has been a major focus of research and development efforts in the pharmaceutical industry for several decades.
Antiretroviral therapy functions by inhibiting viral replication within the body, thereby facilitating immune system restoration and diminishing the likelihood of AIDS-associated complications. One of the key components of ART is the use of HIV injections, which are administered to patients either alone or in combination with other antiretroviral drugs.
According to the European Centre for Disease Prevention and Control, in 2022, 37 of the 49 countries in the Region, including 26 in the European Union/European Economic Area (EU/EEA), reported an increase in HIV diagnoses compared to 2021, with some countries reporting record-high numbers in a single year. Therefore, their demand will continue to grow in this region throughout the forecast period.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe HIV Injection Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $178.5 Million by 2029. The UK market is exhibiting a CAGR of 16.4% during (2023 - 2030). Additionally, The France market would experience a CAGR of 18.2% during (2023 - 2030).
Antiretroviral therapy (ART), the known treatment for HIV, entails the daily administration of a combination of HIV medications. ART can lower the risk of HIV transmission and help individuals with the virus live longer, healthier lives, although it cannot cure HIV. The development of effective treatments for HIV has been a major focus of research and development efforts in the pharmaceutical industry for several decades.
Antiretroviral therapy functions by inhibiting viral replication within the body, thereby facilitating immune system restoration and diminishing the likelihood of AIDS-associated complications. One of the key components of ART is the use of HIV injections, which are administered to patients either alone or in combination with other antiretroviral drugs.
According to the European Centre for Disease Prevention and Control, in 2022, 37 of the 49 countries in the Region, including 26 in the European Union/European Economic Area (EU/EEA), reported an increase in HIV diagnoses compared to 2021, with some countries reporting record-high numbers in a single year. Therefore, their demand will continue to grow in this region throughout the forecast period.
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F.Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Market Report Segmentation
By Distribution Channel- Hospital Pharmacy
- Drugs Stores & Retail Pharmacies
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe HIV Injection Market by Distribution Channel
Chapter 5. Europe HIV Injection Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Gilead Sciences, Inc.
- ImmunityBio, Inc.
- F. Hoffmann-La Roche Ltd.
- Theratechnologies Inc.
- Viriom, Inc.
- AbbVie, Inc.
- Brii Biosciences Limited
- Shionogi & Co., Ltd.
- Boehringer Ingelheim International GmbH
Methodology
LOADING...
